HCA Healthcare Is Maintained at Equal-Weight by Wells Fargo
HCA Healthcare Analyst Ratings
Wells Fargo Maintains HCA Healthcare(HCA.US) With Hold Rating, Raises Target Price to $400
Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Exact Sciences (EXAS) and Crispr Therapeutics AG (CRSP)
Cantor Fitzgerald Maintains HCA Healthcare(HCA.US) With Buy Rating, Raises Target Price to $405
HCA Healthcare Price Target Cut to $440.00/Share From $450.00 by TD Cowen
Leerink Partners Maintains HCA Healthcare(HCA.US) With Buy Rating, Raises Target Price to $460
Oppenheimer Maintains HCA Healthcare(HCA.US) With Buy Rating, Raises Target Price to $400
A Quick Look at Today's Ratings for HCA Healthcare(HCA.US), With a Forecast Between $396 to $460
HCA Healthcare Is Maintained at Outperform by Oppenheimer
HCA Healthcare Analyst Ratings
Leerink Partners Adjusts HCA Healthcare's Price Target to $460 From $465, Keeps Outperform Rating
HCA Healthcare (HCA) Gets a Buy From RBC Capital
Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Viatris (VTRS) and Syndax Pharmaceuticals (SNDX)
Promising Outlook for HCA Healthcare: Strong Fundamentals and Strategic Management Support Buy Rating
Morgan Stanley Maintains HCA Healthcare(HCA.US) With Hold Rating, Maintains Target Price $427
Bernstein Keeps Their Hold Rating on HCA Healthcare (HCA)
HCA Healthcare: Hold Recommendation Amid Modest Misses and External Challenges
Mizuho Securities Maintains HCA Healthcare(HCA.US) With Buy Rating
HCA Healthcare's Strong Q3 2024 Performance Amid Challenges Reinforces Buy Rating